Impact of Disease Staging on Prognosis and Treatment in SCLC
Panel experts review disease staging for limited and extensive stage small-cell lung cancer and discuss the impact of staging on treatment selection.
EP: 1.Importance of Early Referral and Diagnosis in Small-Cell Lung Cancer
Now Viewing
EP: 2.Impact of Disease Staging on Prognosis and Treatment in SCLC
EP: 3.Evolving Role of Biomarkers in SCLC
EP: 4.Patient Scenario 1: Newly Diagnosed ES-SCLC With Presence of Hepatic and Brain Metastases
EP: 5.Expert Insights on First-line Treatment Strategies in SCLC
EP: 6.CASPIAN: Long-Term Follow-up Data and Potential Predictors for Treatment Outcomes
EP: 7.Combination Therapy Approaches With Chemotherapy and Immunotherapy in ES-SCLC
EP: 8.ADRIATIC Trial and Investigational Treatment Approaches for Limited-Stage SCLC
EP: 9.Patient Scenario 2: 1L Management of ES-SCLC Positive for Synaptophysin With a Ki-67 Score of 90%
EP: 10.Real World Data for Combination Strategies With Chemotherapy and Immunotherapy in ES-SCLC
EP: 11.Patient Scenario 3: 2L Lurbinectedin Following 1L Combination IO Chemotherapy
EP: 12.Evolving Treatment Strategies for SCLC in the Second-Line Setting and Beyond
EP: 13.LAGOON and IMFORTE Trials: Data Updates and Expert Insights
EP: 14.2L Dosing Considerations and Management Strategies for SCLC
EP: 15.Novel Treatment Approaches for SCLC and Future Perspectives
Related Videos
Related Content
